J&J drops key cancer trial results as Wall Street eyes stock
Johnson & Johnson (JNJ) spent 2025 proving it could lose a multibillion-dollar drug and still grow. Now it wants to show it can keep doing that for years. On June 13, the company reported results from a late-stage trial of its blood-cancer drug TALVEY, and the data landed at one of the year’s biggest medical […]
